Objectives:
@EN Diabetic peripheral neuropathies are one of the most frequent complications of diabetes,
and multiple metabolic and vascular disturbances are involved in the pathogenetic mechanisms
of diabetic neuropathies.
@ES Methods:
@EN Thirty patients with diabetic neuropathies from ischemic peripheral vascular
disease
were received cilostazol, an antithrombotic and vasodilating drug, 200mg a day in two
divided
doses for eight weeks at the Ewha Womans University Hospital. We analysed the
effects
between before and after treatment with cilostazol.
@ES Results:
@EN 1) Total 30 patients were studied : 21 patients were female and 9 patients were male.
Their mean age was 60.2±9.9 years, and mean duration of diabetes was 8.0±4.9 years.
As
complications, 47% of them had retinopathy and 30% of them nephropathy.
2) No significant difference was found in physical findings, metabolic control states,
CBC,
blood chemistry and lipid levels before and after cilostazol treatment.
3) The score of resting pain and numbness were significantly decreased, and cold
sensation
and claudication were decreased after cilostazol treatment.
4) The score of arterial pulsation and Doppler wave was decreased, and the ankle pressure
index was increased from 1.04±0.07 to 1.08±0.13 after cilostazol treatment, but there was no
statistical significance.
5) Adverse effects were noted in 20% of cilostazol treated patients, 3 cases of headache,
2
facial flush and palpitation and 1 rash and urticaria, respectively.
6) the assessment of overall improvement of the disease, including "markedly
improved",
"improved" and "slightly improved" amounted to 63%. The assessment of overall safety of the
drug, including "safe" and "almost safe" amounted to 80%. The assessment of overall utilility
of the drug, including "very useful", "useful" and "slightly useful" amounted to 63%.
@ES Conclusion:
@EN Cilostazol was useful in the treatment of diabetic patients with peripheral vascular
disease accompanied by ischemic symptoms to improve subjective symptoms and blood flow.
|